首页> 外文期刊>Cell transplantation >Enhanced Antioxidant Capacity of Dental Pulp-Derived iPSC-Differentiated Hepatocytes and Liver Regeneration by Injectable HGF-Releasing Hydrogel in Fulminant Hepatic Failure
【24h】

Enhanced Antioxidant Capacity of Dental Pulp-Derived iPSC-Differentiated Hepatocytes and Liver Regeneration by Injectable HGF-Releasing Hydrogel in Fulminant Hepatic Failure

机译:恶性肝衰竭可注射的HGF释放水凝胶增强牙髓衍生的iPSC分化的肝细胞的抗氧化能力和肝再生

获取原文
获取原文并翻译 | 示例
           

摘要

Acute hepatic failure (AHF) is a severe liver injury leading to sustained damage and complications. Induced pluripotent stem cells (iPSCs) may be an alternative option for the treatment of AHF. In this study, we reprogrammed human dental pulp-derived fibroblasts into iPSCs, which exhibited pluripotency and the capacity to differentiate into tridermal lineages, including hepatocyte-like cells (iPSC-Heps). These iPSC-Heps resembled human embryonic stem cell-derived hepatocyte-like cells in gene signature and hepatic markers/functions. To improve iPSC-Heps engraftment, we next developed an injectable carboxymethyl-hexanoyl chitosan hydrogel (CHC) with sustained hepatocyte growth factor (HGF) release (HGF CHC) and investigated the hepatoprotective activity of HGF CHC-delivered iPSC-Heps in vitro and in an immunocompromised AHF mouse model induced by thioacetamide (TAA). Intrahepatic delivery of HGF CHC iPSC-Heps reduced the TAA-induced hepatic necrotic area and rescued liver function and recipient viability. Compared with PBS-delivered iPSC-Heps, the HGF CHC-delivered iPSC-Heps exhibited higher antioxidant and antiapoptotic activities that reduced hepatic necrotic area. Importantly, these HGF CHC-mediated responses could be abolished by administering anti-HGF neutralizing antibodies. In conclusion, our findings demonstrated that HGF mediated the enhancement of iPSC-Hep antioxidant/antiapoptotic capacities and hepatoprotection and that HGF CHC is as an excellent vehicle for iPSC-Hep engraftment in iPSC-based therapy against AHF.
机译:急性肝衰竭(AHF)是一种严重的肝损伤,导致持续的损伤和并发症。诱导多能干细胞(iPSC)可能是治疗AHF的替代选择。在这项研究中,我们将人类牙髓衍生的成纤维细胞重新编程为iPSC,该iPSC具有多能性并能够分化为包括肝细胞样细胞(iPSC-Heps)在内的三层系。这些iPSC-Heps在基因特征和肝标志物/功能方面类似于人胚胎干细胞衍生的肝细胞样细胞。为了改善iPSC-Heps的植入,我们接下来开发了具有持续肝细胞生长因子(HGF)释放(HGF CHC)的可注射羧甲基-己酰基壳聚糖水凝胶(CHC),并研究了HGF CHC递送的iPSC-Heps在体外和体外的肝保护活性。硫代乙酰胺(TAA)诱导的免疫功能低下的AHF小鼠模型。 HGF CHC iPSC-Heps的肝内递送减少了TAA诱导的肝坏死面积,并挽救了肝功能和受体生存能力。与PBS传递的iPSC-Heps相比,HGF CHC传递的iPSC-Heps表现出更高的抗氧化和抗凋亡活性,减少了肝坏死面积。重要的是,可以通过施用抗HGF中和抗体来消除这些HGF CHC介导的反应。总之,我们的发现表明,HGF介导了iPSC-Hep抗氧化剂/抗凋亡能力和肝保护作用的增强,并且HGF CHC在基于iPSC的抗AHF治疗中是iPSC-Hep植入的优良载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号